MX2023002818A - Oligonucleotido de cadena simple. - Google Patents
Oligonucleotido de cadena simple.Info
- Publication number
- MX2023002818A MX2023002818A MX2023002818A MX2023002818A MX2023002818A MX 2023002818 A MX2023002818 A MX 2023002818A MX 2023002818 A MX2023002818 A MX 2023002818A MX 2023002818 A MX2023002818 A MX 2023002818A MX 2023002818 A MX2023002818 A MX 2023002818A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleotide sequence
- hybridize
- oligonucleotide
- stranded oligonucleotide
- nucleotides
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 6
- 125000003729 nucleotide group Chemical group 0.000 abstract 9
- 239000002773 nucleotide Substances 0.000 abstract 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 102100034343 Integrase Human genes 0.000 abstract 1
- 101710203526 Integrase Proteins 0.000 abstract 1
- 108091028664 Ribonucleotide Proteins 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000002336 ribonucleotide Substances 0.000 abstract 1
- 125000002652 ribonucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03067—Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporciona un oligonucleótido de cadena simple que es capaz de controlar un gen objetivo con alta eficiencia y puede producirse fácilmente; el oligonucleótido de cadena simple es representado por la fórmula X-L-Y en donde X y Y se hibridan mediante una primera porción de la secuencia de nucleótidos y una segunda porción de la secuencia de nucleótidos; X está compuesta de 7 a 100 nucleótidos, contiene por lo menos un nucleótido modificado, y tiene una primera secuencia de nucleótidos que es capaz de hibridarse con un segundo oligonucleótido y contiene por lo menos cuatro nucleótidos contiguos reconocidos por RNasa H; Y está compuesta de 4 a 100 nucleótidos, y tiene una segunda secuencia de nucleótidos que es capaz de hibridarse con un segundo oligonucleótido y contiene por lo menos un ribonucleótido; por lo menos una de la secuencia de nucleótidos X y la secuencia de nucleótidos Y tiene una secuencia antisentido capaz de hibridarse con un ARN objetivo; L es un grupo derivado de un tercer oligonucleótido que se degrada bajo condiciones fisiológicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016012804 | 2016-01-26 | ||
JP2016158833 | 2016-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023002818A true MX2023002818A (es) | 2023-03-17 |
Family
ID=59398721
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009090A MX2018009090A (es) | 2016-01-26 | 2017-01-26 | Oligonucleótido de cadena simple. |
MX2023002818A MX2023002818A (es) | 2016-01-26 | 2018-07-25 | Oligonucleotido de cadena simple. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018009090A MX2018009090A (es) | 2016-01-26 | 2017-01-26 | Oligonucleótido de cadena simple. |
Country Status (10)
Country | Link |
---|---|
US (2) | US11530409B2 (es) |
EP (1) | EP3409779A4 (es) |
JP (3) | JP6988481B2 (es) |
CN (2) | CN116064544A (es) |
AU (1) | AU2017211461B2 (es) |
BR (1) | BR112018015164A2 (es) |
CA (1) | CA3023222A1 (es) |
MX (2) | MX2018009090A (es) |
TW (2) | TWI803455B (es) |
WO (1) | WO2017131124A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116064544A (zh) | 2016-01-26 | 2023-05-05 | 日产化学株式会社 | 单链寡核苷酸 |
CA3052801A1 (en) * | 2017-02-06 | 2018-08-09 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
US11555188B2 (en) | 2017-07-26 | 2023-01-17 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
AU2019237599A1 (en) | 2018-03-20 | 2020-11-12 | Nissan Chemical Corporation | Antisense oligonucleotide having reduced toxicity |
US20220162607A1 (en) | 2019-03-14 | 2022-05-26 | Rena Therapeutics Inc. | Nucleic acid complex for modulating ihh expression |
EP4098747A1 (en) | 2020-01-31 | 2022-12-07 | Sanwa Kagaku Kenkyusho Co., Ltd. | Antisense oligonucleotide of atn1 |
EP4116419A1 (en) | 2020-03-04 | 2023-01-11 | Nissan Chemical Corporation | Antisense oligonucleotide of calm2 |
JPWO2022211129A1 (es) * | 2021-04-01 | 2022-10-06 | ||
EP4353266A1 (en) | 2021-05-31 | 2024-04-17 | Rena Therapeutics Inc. | Ligand-bound nucleic acid complex |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08154687A (ja) | 1994-12-12 | 1996-06-18 | Yamanouchi Pharmaceut Co Ltd | アンチセンスオリゴヌクレオチド及び抗ウイルス剤 |
JPH09110894A (ja) | 1995-10-17 | 1997-04-28 | Soyaku Gijutsu Kenkyusho:Kk | ハイブリッドdna/rnaオリゴヌクレオチド及び抗ウイルス剤 |
US20040171028A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
JPH11137260A (ja) | 1997-11-06 | 1999-05-25 | Soyaku Gijutsu Kenkyusho:Kk | 抗インフルエンザウイルス環状ダンベル型rna−dnaキメラ化合物及び抗インフルエンザウイルス剤 |
AU6055299A (en) | 1998-09-21 | 2000-04-10 | Ribozyme Pharmaceuticals, Inc. | Hairpin hybridizer molecules for modulation of gene expression |
AU2395900A (en) * | 1998-12-31 | 2000-07-31 | Gene Logic, Inc. | Assay device comprising mixed probes |
MXPA01011708A (es) * | 1999-06-25 | 2003-09-10 | Insight Strategy & Marketing | Polinucleotidos que codifican polipeptidos distantemente homologos a heparanasa. |
EP1627061B1 (en) * | 2001-05-18 | 2009-08-12 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
US20070032441A1 (en) * | 2001-05-18 | 2007-02-08 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
EP2221377B2 (en) * | 2002-02-01 | 2017-05-17 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
WO2003068795A1 (fr) | 2002-02-13 | 2003-08-21 | Takeshi Imanishi | Analogues de nucleoside et derive d'oligonucleotide comprenant un analogue nucleotidique de ces composes |
AU2003213203A1 (en) | 2002-02-20 | 2003-09-09 | Ribozyme Pharmaceuticals, Incorporated | Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways |
GB0205455D0 (en) * | 2002-03-07 | 2002-04-24 | Molecular Sensing Plc | Nucleic acid probes, their synthesis and use |
EP2258847B2 (en) | 2002-08-05 | 2020-07-01 | Silence Therapeutics GmbH | Futher novel forms of interfering RNA molecules |
US20040058886A1 (en) | 2002-08-08 | 2004-03-25 | Dharmacon, Inc. | Short interfering RNAs having a hairpin structure containing a non-nucleotide loop |
AU2003291721A1 (en) * | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
AU2003299864A1 (en) | 2002-12-27 | 2004-07-29 | P. Radhakrishnan | Sirna compounds and methods for the downregulation of gene expression |
JP4948163B2 (ja) * | 2003-05-23 | 2012-06-06 | サーナ・セラピューティクス・インコーポレイテッド | 化学修飾した低分子干渉核酸(siNA)を使用する遺伝子発現のRNA干渉仲介抑制 |
CA2528597C (en) | 2003-06-11 | 2014-08-05 | Hybridon, Inc. | Stabilized immunomodulatory oligonucleotides |
DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
CN101155918A (zh) * | 2005-02-01 | 2008-04-02 | 爱尔康公司 | RNAi介导的高眼压靶标的抑制 |
EP2052079A2 (en) * | 2006-07-17 | 2009-04-29 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
CN101301478A (zh) * | 2007-05-10 | 2008-11-12 | 贝勒医学院 | 以低氧诱导因子1-α(HIF1α)作为靶标的G-四合体寡核苷酸 |
EP2321414B1 (en) * | 2008-07-25 | 2018-01-10 | Alnylam Pharmaceuticals, Inc. | Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand |
EP2454371B1 (en) | 2009-07-13 | 2021-01-20 | Somagenics, Inc. | Chemical modification of small hairpin rnas for inhibition of gene expression |
WO2011052436A1 (ja) | 2009-10-29 | 2011-05-05 | 国立大学法人大阪大学 | 架橋型人工ヌクレオシドおよびヌクレオチド |
MX2012010479A (es) * | 2010-03-08 | 2012-10-09 | Monsanto Technology Llc | Moleculas polinucleotidicas para regulacion genetica en plantas. |
DK2558578T3 (en) | 2010-04-13 | 2016-01-25 | Life Technologies Corp | CONFIGURATIONS AND METHODS FOR INHIBITION OF nucleic acid function |
WO2011156202A1 (en) | 2010-06-08 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
US8785121B2 (en) | 2010-07-08 | 2014-07-22 | Bonac Corporation | Single-stranded nucleic acid molecule for controlling gene expression |
KR101894701B1 (ko) | 2010-08-03 | 2018-09-04 | 가부시키가이샤 보낙 | 함질소 지환식 골격을 갖는 일본쇄 핵산 분자 |
WO2013040429A1 (en) * | 2011-09-14 | 2013-03-21 | Rana Therapeutics Inc. | Multimeric oligonucleotide compounds |
CA3106312A1 (en) | 2011-12-16 | 2013-06-20 | National University Corporation Tokyo Medical And Dental University | Chimeric double-stranded nucleic acid |
US9528111B2 (en) | 2012-01-07 | 2016-12-27 | Bonac Corporation | Single-stranded nucleic acid molecule having amino acid backbone |
US20150247141A1 (en) | 2012-09-14 | 2015-09-03 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
CN103114131B (zh) * | 2012-11-30 | 2018-10-02 | 珠海市坤元农业科技有限公司 | 一种引物中部序列干扰pcr技术 |
CN103333890B (zh) * | 2012-12-21 | 2015-04-15 | 厦门成坤生物技术有限公司 | 治疗乙型病毒性肝炎的rna干扰制剂 |
IL284593B2 (en) | 2013-05-01 | 2023-02-01 | Ionis Pharmaceuticals Inc | Compositions and methods for modulation of hbv and ttr expression |
US11028387B2 (en) | 2013-05-30 | 2021-06-08 | National University Corporation Tokyo Medical And Dental University | Double-stranded agents for delivering therapeutic oligonucleotides |
CN104419702A (zh) * | 2013-09-04 | 2015-03-18 | 北京中康万达医药科技有限公司 | 一种基于生物信息学筛选siRNA的方法 |
CN106068324B (zh) | 2013-12-27 | 2020-12-29 | 株式会社博纳克 | 控制基因表达的人工匹配型miRNA及其用途 |
WO2015105083A1 (ja) | 2014-01-07 | 2015-07-16 | 塩野義製薬株式会社 | アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド |
WO2015113922A1 (en) * | 2014-01-30 | 2015-08-06 | Roche Innovation Center Copenhagen A/S | Poly oligomer compound with biocleavable conjugates |
JPWO2016152352A1 (ja) * | 2015-03-20 | 2018-01-11 | 国立大学法人名古屋大学 | メラノーマ特異的バイオマーカー及びその利用 |
CN116064544A (zh) * | 2016-01-26 | 2023-05-05 | 日产化学株式会社 | 单链寡核苷酸 |
US11878060B2 (en) * | 2016-08-07 | 2024-01-23 | Novartis Ag | mRNA-mediated immunization methods |
CA3052801A1 (en) * | 2017-02-06 | 2018-08-09 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
US11555188B2 (en) * | 2017-07-26 | 2023-01-17 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
AU2019237599A1 (en) * | 2018-03-20 | 2020-11-12 | Nissan Chemical Corporation | Antisense oligonucleotide having reduced toxicity |
EP3650559B1 (en) * | 2018-11-08 | 2022-06-29 | Siemens Healthcare GmbH | Direct rna nanopore sequencing with help of a stem-loop polynucleotide |
WO2020154344A1 (en) * | 2019-01-22 | 2020-07-30 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
EP4116419A1 (en) * | 2020-03-04 | 2023-01-11 | Nissan Chemical Corporation | Antisense oligonucleotide of calm2 |
-
2017
- 2017-01-26 CN CN202211379310.XA patent/CN116064544A/zh active Pending
- 2017-01-26 CN CN201780008239.5A patent/CN108884462B/zh active Active
- 2017-01-26 TW TW106103330A patent/TWI803455B/zh active
- 2017-01-26 JP JP2017563832A patent/JP6988481B2/ja active Active
- 2017-01-26 EP EP17744354.6A patent/EP3409779A4/en active Pending
- 2017-01-26 BR BR112018015164A patent/BR112018015164A2/pt unknown
- 2017-01-26 WO PCT/JP2017/002831 patent/WO2017131124A1/ja active Application Filing
- 2017-01-26 CA CA3023222A patent/CA3023222A1/en active Pending
- 2017-01-26 TW TW112115168A patent/TW202334427A/zh unknown
- 2017-01-26 AU AU2017211461A patent/AU2017211461B2/en active Active
- 2017-01-26 US US16/073,114 patent/US11530409B2/en active Active
- 2017-01-26 MX MX2018009090A patent/MX2018009090A/es unknown
-
2018
- 2018-07-25 MX MX2023002818A patent/MX2023002818A/es unknown
-
2021
- 2021-12-01 JP JP2021195231A patent/JP7435583B2/ja active Active
-
2022
- 2022-11-11 US US18/054,660 patent/US20230203498A1/en active Pending
-
2024
- 2024-02-08 JP JP2024017718A patent/JP2024056807A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022050389A (ja) | 2022-03-30 |
US11530409B2 (en) | 2022-12-20 |
CN116064544A (zh) | 2023-05-05 |
TW202334427A (zh) | 2023-09-01 |
WO2017131124A1 (ja) | 2017-08-03 |
TWI803455B (zh) | 2023-06-01 |
JP2024056807A (ja) | 2024-04-23 |
US20190119683A1 (en) | 2019-04-25 |
JPWO2017131124A1 (ja) | 2018-11-15 |
MX2018009090A (es) | 2019-03-28 |
CN108884462B (zh) | 2022-11-25 |
TW201738376A (zh) | 2017-11-01 |
CA3023222A1 (en) | 2017-08-03 |
CN108884462A (zh) | 2018-11-23 |
AU2017211461A1 (en) | 2018-09-13 |
EP3409779A4 (en) | 2019-07-03 |
JP6988481B2 (ja) | 2022-01-05 |
AU2017211461B2 (en) | 2023-01-12 |
BR112018015164A2 (pt) | 2018-12-26 |
EP3409779A1 (en) | 2018-12-05 |
US20230203498A1 (en) | 2023-06-29 |
JP7435583B2 (ja) | 2024-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023002818A (es) | Oligonucleotido de cadena simple. | |
WO2018041973A9 (en) | Chemically modified single-stranded rna-editing oligonucleotides | |
MX2019009305A (es) | Oligonucleotido de cadena simple. | |
WO2017037304A3 (en) | An assembly system for a eukaryotic cell | |
NZ595955A (en) | Oligonucleotide comprising an inosine for treating dmd | |
JP2016526529A5 (es) | ||
JP2017002079A5 (es) | ||
MX2010004984A (es) | Uso de oligonucleotidos con bases modificadas en hibridacion de acidos nucleicos. | |
TR201908969T4 (tr) | Rnaı indüklü huntıngtın geni supresyonu. | |
MX2020001158A (es) | Composiciones nucleotidicas modificadas con citidina-5-carboxamida y metodos relacionados con las mismas. | |
IN2013MN00522A (es) | ||
WO2005089287A3 (en) | Methods and compositions for the specific inhibition of gene expression by double-stranded rna | |
EP4219741A3 (en) | Closed nucleic acid structures | |
PH12014501436B1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
NZ563845A (en) | RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic | |
UA104131C2 (uk) | Модифікована ліпідом дволанцюжкова рнк, яка має сильний ефект рнк-інтерференції | |
JP2016528887A5 (es) | ||
NZ630890A (en) | Microrna compounds and methods for modulating mir-122 | |
MX2011009597A (es) | Deteccion mejorada de la expresion del gen. | |
AR100946A1 (es) | Composiciones y métodos para regular la expresión génica por medio de la interferencia de arn | |
MD20170014A2 (ro) | Metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D | |
MX2018012695A (es) | Oligomeros antisentido y metodos de uso de los mismos para tratar enfermedades relacionadas con el gen alpha-glucosidasa acido. | |
MX2018002998A (es) | Derivado de acido nucleico que tiene actividad inmunoestimuladora. | |
EP4253544A3 (en) | Modified messenger rna comprising functional rna elements | |
MX2020010802A (es) | Moleculas inhibidoras de acidos nucleicos de caracter bicatenario modificadas con nucleotidos que aumentan la tm. |